The following are results of research done in China.
which are provided for your information only.
Medical claims are not allowed in Canada or the USA,
YU-CCAN & CANAID are sold as food supplements.
|
The following pages contain detailed
CLINICAL STUDIES
in the COMBINED USE of
YU-CCAN HERBAL DRINK
&
CANAID HERBAL TEA
|
A Study on the Tumor-Inhibition Effect of
Combined Use of CANAID and YU-CCAN
|
|
|
|
Imported from Canada CANAID and YU-CCAN are oral liquid medicine
extracted from pure natural plants and have been used abroad,
especially in North America for seventy years. The preliminary
clinical studies in China have shown that the combined use of
the two drugs has favorable therapeutical effect on tumor and
various diseases resulting from immunologic deficiency. To provide
laboratory evidence for further promotion of the two drugs on
clinical use, we studied the tumor-inhibition effect of the
combined use of the two drugs on mice contracted with cancer.
This study was conducted according to the "Guidelines on
Pre-clinical Study of New Chinese Medicine", Ministry of
Health,1993.
Materials and Methods
Animals: NIH mice, weight 18 - 22 g, healthy, male, provided
by the medical experimental animal farm administered by the
Health Department of Guangdong Province.
Cancer Strain: mice hepatic carcinoma, provided by The Tumor
Research Institute of Zhongshan University of Medicine.
Drugs to be tested: CANAID and YU-CCAN, oral liquid. Prior to
the test, the liquid was condensed to a suitable concentration
for experimental use.
Following aseptic manipulation, the mice hepatic carcinoma strain
liquid was first diluted with physiological saline at a ratio
of 1:1. Each mouse was then subcutaneously vaccinated with 0.2
ml. of the cancer-carrying liquid in the auxiliary fossa. On
the following day, the mice were randomly divided into five
groups according to their weight, with the weight difference
within each group being no more than 1 gram. The mice were then
gastro-fed with CANAID, and then YU-CCAN one hour later. The
dosages were as follows (all in terms of the original concentration):
High dosage group(HD): CANAID 540 ml/kg, YU-CCAN 80 ml/kg;
Intermediate dosage group (ID): CANAID 270 ml/kg, YU-CCAN 40
ml/kg;
Low dosage group (LD): CANAID 135 ml/kg, YU-CCAN 20 ml/kg.
In addition, there were two contrast groups, one was positive
with 5 - Fu 10 mg/kg (to be referred as 5- Fu), the other was
negative with physiological saline (equal dosage, 20 ml/kg,
to be referred as PS). The drugs were given consecutively for
10 days. The next day following the withdrawal of the drugs,
the mice were killed and the tumor masses were taken out and
weighed. Tumor inhibition rates (to be referred as TIR) were
calculated and the data were analyzed statistically.
|
| |
|
Results
|
| |
| According to the "GUIDELINES ON PRE-CLINICAL STUDY OF NEW
CHINESE MEDICINE", the test was conducted three times, and
the results are listed in the following table. |
| |
| |
Test
One
|
Test
Two
|
Test
Three
|
|
Group
|
Tumor
Wt (g)
|
Tir
(%)
|
Tumor
Wt (g)
|
Tir
(%)
|
Tumor
Wt (g)
|
Tir
(%)
|
|
PS
HD
ID
LD
5-Fu
|
1.77+/-0.31
1.39+/-0.35*
1.24+/-0.56*
1.63+/-0.38
|
22
30
8
|
1.24+/-0.49
0.84+/-0.29*
0.8 +/-0.29*
0.85+/-0.27*
0.51+/-0.08***
|
32.3
35.5
31
58.9
|
2.51+/-0.3
1.37+/-0.28**
1.33+/-0.38**
1.43+/-0.26**
1.12+/-0.27**
|
45.5
47.0
42.9
55.4
|
|
| |
| Compared to the group of physiological Saline (PS): *P <0.05;
**P< 0.01; ***P <0.001 |
| |
| From the above table, one can see that for the group of intermediate
dosage, the tumor- inhibition rate was greater than 30% for all
the three tests. In addition, for every test, the results were
significant or notably significant compared to those of the physiological
saline group. For the high dosage group, only the first test had
a tumor-inhibition rate lower than 30%, but the results were significant
for all the three tests. For the low dosage group, the tumor-inhibition
rate of the first test was lower than 30% and was not statistically
significant. However, for the remaining two tests the tumor-inhibition
rate was greater than 30%, and also significant statistically.
|
| |
| Discussions |
| |
| 1. According to "GUIDELINES ON PRE-CLINICAL STUDY OF NEW
CHINESE MEDICINE", if a drug has a statistically significant
tumor-inhibition rate of 30% on animal transplantational tumor,
the drug is classified as having tumor-inhibition effect. The
current laboratory study has shown that the combined use of CANAID
and YU-CCAN had notable tumor-inhibition effect, with the intermediate
dosage group being the most significant. The tumor-inhibition
rate of high dosage group was slightly lower than that of the
intermediate group, but the difference was not statistically significant
(P > 0.05). This indicates that increasing dosage does not
increase the tumor inhibition effect. |
| |
2. During the laboratory test, the cancer-carrying mice undergoing
treatment of the two drugs had better general appearing, activity
level, and appetite compared to the negative contrast group indicating
that the combined use of the two drugs can also improve the general
status of the cancer-carrying animals, i.e., improve the quality
of their lives.
|
| |
|
Research
Section of Pharmacology Institute
of Material Medica of Guangdong Province
|
|
----------------------------------------------------------------------------------------------
|
|
|
YU-CCAN
HERBAL DRINK
ACUTE TOXICITY TEST
|
| |
|
|
|
Performed
by: Guangdong Provincial Institute of Material Medica, Pharmacology
Department
|
|
|
.
| 1. |
Medicine Test: Yu-ccan Herbal Drink, supplied
by Guangdong Star Medicine Science and Technology Development
Company |
|
|
| 2. |
Testing Animal: NIH breed mice supplied by Guangdong
Provincial Experiment Animal Farm |
|
|
| 3. |
Experiment Procedure and Result: |
|
|
|
a.
|
Medicine Treatment: Condense 1,000 ml. of Yu-ccan
Herbal Drink into 100 ml. over double boiler to be used
in the experiment. |
|
|
|
|
b.
|
Acute Toxicity test through oral administration on
mouse: Select 30 mice weight between 20 to 22 g. 15
MALE AND 15 FEMALE. Feed mice with the entire dosage condensed
Herbal Drink - (equivalent to the strength of 70.61 ml/kg.
of the original medicine). Observe mice for 7 days after
feeding. All mice survived with a normal appetite. It
is observed that the mice can take up to 70.61 ml./kg.
of Yu-ccan Herbal Drink orally without any problem. (For
an average adult of 50 kg. in China, normal dosage is
30 ml. per day orally.) The dosage in this test is equivalent
to 117 times of the normal dosage. The dosage of 20 ml.
per day, per adult is recommended for clinical testing. |
|
It is concluded that oral administration of the YU-CCAN
Herbal Drink is safe.
---------------------------------------------------------------------------------------------
|
|
|
CANAID
HERBAL DRINK
ACUTE TOXICITY TEST
|
| |
|
Performed
by : Guangdong Provincial Institute of Material Medica, Pharmacology
Department Mr. L.ul & Ms. Chan
|
| |
|
|
|
Objective
|
| To observe the acute toxic reaction of white
mice following the oral administration of CANAID herbal drink.
|
| |
| 1. |
Medicine Test: CANAID Herbal Drink, provided by
Guangdong Star Medicine Science and Technology Development
Company. |
|
|
| 2. |
Testing Animal: NIH breed white mice, weight 20-22g,
provided by Guangdong Provincial Experiment Animal Farm.
|
|
|
| 3. |
Experiment Procedure and Result: |
|
|
|
a.
|
Medicine Treatment: Condense l,000 ml of CANAID
Herbal Drink into 20 ml over double boiler to be used in
the experiment. |
|
|
|
|
b.
|
Acute Toxicity test through oral administration on
mouse: Select 30 white mice weight between 20 to 22g
each,15 male and 15 female. Mouth feed mice with condensed
herbal drink according to 0.4 ml/10 g (equivalent to the
strength of 2,000 ml/kg of the original medicine) all at
once. Observed continuously for 7 days after feeding. All
mice survived with normal appetite and vitality. It is concluded
that the mice can take up to 2,000m/kg. of CANAID Herbal
Drink. This dosage is equivalent to 555 times of the normal
daily dosage of an adult or 1,666 times of one normal dosage
of an adult. |
|
| |
|
It is concluded that oral administration
of the CANAID Herbal Drink is safe.
|
|
---------------------------------------------------------------------------------------------
|
| |
Clinical
Summary on Taking CANAID
and YU-CCAN from 583 Cases
|
|
|
| |
Clinical Summary on Taking CANAID and YU-CCAN from 583 Cases
Reference Room, Ganaid (Hong Kong) International Company Ltd.
With the trend of physiocracy gaining momentum, wide spread promotion
of two herbal pharmaceutics originated from aboriginal peoples
in Canada - CANAID and Yu-ccan health teas is under way. Both
drugs are safe and nontoxic drinks capable of effectively increasing
and adjusting the function of the immunologic system of the body.
The nontoxic nature of the pharmaceutics has been affirmed by
American FDA and Canadian Health Bureau.
"Tea", in fact, is a drug of easy-taking and enjoyable.
The two drugs have been used clinically in North America for over
seventy years and have very favorable clinical cases to support.
The promotion of the two drugs in Hong Kong has also shown that
the drugs are very effective on cancers, asthma, rhinallergosis,
lupus erythematosus, etc. To provide more convincing evidence,
we are now summarizing the related clinical cases as follows:
|
| |
| I. General Information |
| |
| 1. |
|
Cases:583 Sex:
|
Male: 216 |
Female: 367 |
| |
Ages: 4 to 82 |
Average: 40 |
|
|
|
| 2. |
|
Categories of Diseases: 4, with the number of cases
being:
|
| |
Cancer: 288 |
Asthma: 84 |
| Phinallergosis: 176 |
Lupus Erythematosus: 35 |
|
|
| |
| II. Diagnosis Standards |
| |
| The selection of the cases was based on the diagnosis standards
of American "Internal Medicine of Hlss", British "Davidson's
Principles and Practice of Medicine" and Chinese "Practical
Internal Medicine". |
| |
| III. Estimation Standards |
| |
| In order to evaluate the clinical effect of CANAID and YU-CCAN
on the Chinese population, we selected some cases from Guangdong
province. The results are summarized as follows: |
| |
| Healing: |
Symptoms disappeared and all examination results returned
to normal |
| Notably Effective:
|
Symptoms basically disappeared; and all examination results
basically returned to normal |
| Effective: |
Symptoms remitted to some extent, and all examinations
showed some improvements |
| Ineffective: |
None of the symptoms showed any changes, or only some
of the symptoms had minor changes |
|
| |
| IV.
Method of Administration Dosage and Precautions |
| |
| |
CANAID: 60 ml
T.D.I. |
. |
YU-CCAN: 30
ml Q.D |
|
| The above dosages were administered to the same
patient. |
| |
| CANAID should be diluted with twice as much (ie., 120 ml) distilled
water and served warm with empty stomach, and should not be administered
with boiled tap water or tea. If no distilled water was available,
CANAID could be administered directly. Adding distilled water
remained the better option for the following reasons: (1) Distilled
water is pure water, hence is helpful in discharging toxic substances;
(2) The sodium contained in boiled water or other water will interact
with some components of CANAID, reducing the effectiveness of
the latter. |
| |
| In addition, taking cold, directly out of the refrigerator
CANAID could not be absorbed effectively, causing waste, hence
should be warmed up to improve absorption. |
| |
|
V.
Results
|
| |
Overall Estimation:
|
|
Healing
|
Notably Effective
|
Effective
|
Ineffective
|
| Disease |
TOTAL
|
Cases
|
%
|
Cases
|
%
|
Cases
|
%
|
Cases
|
%
|
|
Cancer
Asthma
Phinallergosis
Lupus
Erythematosus
|
288
84
176
35
|
11
8
1
|
13.09
4.54
2.86
|
|
50.37
35.71
54.54
57.14
|
100
36
63
11
|
34.70
42.86
35.79
31.43
|
43
7
9
3
|
14.93
8.33
5.11
7.14
|
| SUM TOTAL |
583
|
20
|
3.43
|
291
|
49.91
|
210
|
36.02
|
62
|
10.63
|
|
| |
Other therapeutical
effects:
Besides the above effects, there were also cases showing that
the use of CANAID could result in notable improvements on the
following diseases: diabetes, arthritis, dermatomycosis, gray
nail, mylasis, hoary hair etc. |
| |
| VI.
Toxic Reactions |
| |
| During the clinical use of CANAID, there were 31 cases showing
uncomfortable symptoms: temporary decrease of physical strength,
hyposthenia and 18 cases showing abdominal distension, constipation,
diarrhea, and uncomfortable feeling in the abdomen. No withdrawal
of the drugs and special treatments were needed since the toxic
reactions remitted spontaneously with continued use of CANAID. |
| |
| Vll. Typical Cases |
| |
| 1. Jie
He, male, 70 years old. He was admitted to Guangzhou City No.1
People's Hospital, complaining "pain in the neighborhood
of stomach". His illness was then diagnosed as "adenocarcinoma
of pancreas". Ultrasonic wave examination showed the following:
(1) Liver was larger than normal, and the acoustic image was of
biliary hepatocirrhosis. (2) The internal and external biliary
ducts of liver expanded and the lower section of the common bile
duct was blurred. (3) The gallbladder was enlarged and there was
cholecystitis. (4) The head of pancreas was enlarged, the echo
was low, and space occupying lesion of pancreas could not be ruled
out. (Gallbladder: 7.6 x 4.0 cm; head of pancreas: 3.5 cm; body
of pancreas: 1.5 cm; tall of pancreas: 1.3 cm; internal echo was
low, and the borders were blurred.) No improvement was seen after
treatment; on the contrary, the symptoms exacerbated with more
uncomfortable feeling, jaundice, pan-fever, "As if entering
a volcano", completely loss of appetite, hoarseness, etc.
At that time, the wife of the patient brought back CANAID Herbal
Tea and YU-CCAN Herbal Tea from Hong Kong. With the thought of
giving them a try, the patient started drinking the herbal teas.
Surprisingly, after drinking three times, on the next day, the
patient wanted to eat. Within three months of drinking the teas,
the Jaundice disappeared, appetite returned to normal, the face
was flushing, the gray hair gradually turned black, the patient
was healed and released from hospital. |
| |
| 2. Dequn
Yao, female, 51 years old. On April 1, 1994, the patient underwent
an "intestinal cancer removal operation" at Nadasu Hospital
of Hong Kong. After the operation, the patient was treated with
chemotherapy. Without any improvement, the patient still had the
following symptoms: asthenia, hyphemia, lassitude, hematochezia.
When the patient was re-hospitalized on March 20, 1S94, it was
found that the tumor had transferred to liver, and an operation
was needed. When the patient was hesitating, her younger sister
recommended CANAID Herbal Tea and YU-CCAN Herbal Tea to her. Upon
drinking the teas, within a couple of days, the following appeared:
(1) Secretion from nasal cavity was increased and black ball shaped
substances were spitted out; (2) Large amount of black watery
feces were defecated, and the spirit and appetite were improved.
With the continued use of the teas, the magnetic resonance scan
on May 10 found that the two shadows in the liver had disappeared,
and the doctor considered that an operation was no longer needed.
The patient was required to be reexamined after three months.
|
| |
| 3. Shuhua
Li, female, 48 years old. The patient was diagnosed to have "lymph
node cancer on the left neck" at Sha Tian Prince of Wales
Hospital in Hong Kong in September, 1993. In October, the patient
underwent a cancer removal operation followed by electrotherapy.
Without any improvement, the cancer was found on April 13, 1994
to have transferred to the supraclavicular lymph nodes on the
right side of the neck with a size of about 4 cm. With the recommendation
of a friend the patient started drinking Canaid Herbal Tea and
Yuccan Herbal tea on April 22. On June 2 (after drinking the teas
for over a month) the enlarged lymph nodes had reduced to 0.5
cm. On June 28, the tumor had disappeared. |
| |
| 4. Shuqin
Li, female, 56 years old. The patient had a long medical history
of "anaphylactic asthma" with symptoms of being afraid
of cold, sweating, arthralgia. Examinations at Beijing Concord
Hospital verified that the patient was allergic to dust and moisture,
having tremendous inconvenience in daily life. After drinking
CANAID Herbal Tea and YU-CCAN Herbal Drink for 18 days, the general
health had improved. Although the patient still had asthma, the
severity had been reduced, and the pantalgia was alleviated. Three
months later, the patient completely recovered, with full vitality,
normal appetite, gained bodily weight, and no allergic reaction
even walking through refrigeration room. |
| |
| 5. Nuoting
Yang, female, 30 years old. The patient's illness was diagnosed
as lupus erythematosus in November,1985 at the Nan Kui Yong Clinic
of Hong Kong. She was treated with hormone, with fluctuating results.
Two to three years later, she also contracted another disease:
"chronic nephritis", and suffered from anasarca, the
side effect of the hormone treatment. Since the diseases were
not under control, she was then treated with "anticancer
injection", without satisfactory effect. The urinary protein
level reached above 9.0. In April 1993, she started drinking CANAID
Herbal Tea and YU-CCAN Herbal Drink which were recommended by
a friend. At the beginning, due to the lack of confidence and
insufficient dosage, no effects were observed. Then, the dosage
of CANAID was increased, with the hope of a last try. Two months
later, the urinary protein level was reduced to 2.0. The doctor's
analysis was as follows: Because of the prolonged suffering of
chronic nephritis, the kidney might have been damaged. Therefore,
the patient's condition should be considered as under control,
although the urinary protein level was maintained at 2.0. The
patient's vitality and self- feeling were good enough to be considered
as having recovered. |
| |
| Vlll. Discussions |
| |
CANAID:
Essential ingredients: burdock root, rhubarb
root, slippery elm bark, sheep sorrel.
Burdock is one of the best herbs for cleansing blood, since
it can effectively remove the acid substances in blood. Burdock
root can make the pituitary gland secrete large amount of proteins
and help balance the hormones of the body.
Rhubarb root has lightly purgative, hemostatic, and tonic
function.
Slippery elm bark can improve the functions of adrenal
gland, help producing blood, and clean undesirable impurities
from many organs of the body.
Sheep sorrel can remove the putrid substances from blood.
The human body constantly absorbs all kinds undesirable and toxic
substances from various sources: the additives and pigments in
food, the carcinogenic substances in the pesticide and drinking
water, the pollutants in the air, etc. If the toxic substances
are allowed to accumulate in the body, the immunologic system
may be inhibited or damaged to some extent. In this case, various
diseases may be contracted: cancer, asthma, allergy, rheumatic
arthritis, internal secretion imbalance, etc. CANAID can remove
the toxic substances from the body in a short time. |
| |
|
YU-CCAN Herbal Drink:
Essential ingredients: schidigera yucca, licorice
root, fennel seed, clove buds, anise seed, cinnamon bark, honey.
Schidigera yucca has been used for hundreds of years
to treat pain, wounds, and skin rash, etc.
Licorice root can strengthen the functions of adrenal
gland, making the adrenal cortex produce more cortisone and
aldosterone. Fennel seed has sedative effect on the nerves,
and hence it can help remove the impurities from the body, alleviate
pains, stop convulsion, and help with digestion.
Clove buds contain the strongest bactericide. It can
also help with blood circulation, digestion, and increase the
nutrition absorption capacity of the body.
Anise seed can dissolve the catarrh of the digestion
system or between the nose and throat.
Cinnamon bark can eliminate flatulence from the gastrointestinal
tract, and enforce the digestive function of the stomach.
|
| |
| Because of the eating habits of our modern human being, the
toxic substances in the preservatives, pigments, pesticides, etc.
gradually form a thick mucous membrane in the intestinal cavity.
The membrane reduces our capacity to absorb nutrition from the
food, and makes the ferment secretion of the beneficial bacteria
abnormal, severely disrupting the immunologic functions of the
body. According to medical researches conducted in the United
States, more than ninety percent of the internal diseases were
caused by the mucous membrane. If the accumulated toxic substances
are removed from the intestinal duct, many diseases will be eliminated
automatically. Schidigera yucca in YU-CCAN, a plant of Liliaceae
growing in desert, is a natural detergent of the human body. It
can help discharge the accumulated toxic waste in the intestines
out of the human body, increase the absorbing capacity, increase
and adjust the ferment secretion of the intestinal cavity, and
improve blood circulation and immunologic function. |
| |
| CANAID and YU-CCAN are like a catalyst for the whole body. They
provide the most important condition for recovering - disinfection.
Therefore, the blood becomes clean - the oxygen carrying capacity
is increased - the ferment making returns to normal - the immunologic
adjusting function becomes more sensitive - and anti-disease ability
is increased. Therefore, notable clinical effects may be observed.
|
| |
| IX. Summary |
| |
This article has summarized 583 cases of taking CANAID and YU-CCAN
(288 cases of cancer, 84 cases of asthma,176 cases of rhinallergosis,
35 cases of lupus erythematosus). Of the 288 cases of cancer patients,
145 cases were notably effective, accounting for 50.37%; 100 cases
were effective, accounting for 34.70%. The most effective cases
were observed on the patients with intestinal cancer, malignant
lymphoma, nasopharyngeal carcinoma, leukemia. Of the 84 cases
of asthma,11 were healed, 30 were notably effective, 36 were effective,
and the total effective rate was 92.47%. Of the 176 cases of rhinallergosis,
the total effective rate was 94.89%. For the 35 cases of lupus
erythematosus, the total effective rate was 92.86%. Generally
speaking, the combined use of CANAID and YU-CCAN on the same patient
was very effective on strengthening/adjusting the function of
the immunologic system of the human body. Otherwise, the independent
use of either of the drugs was not as effective. For more than
seventy years, the two drugs have been indeed effective in cancer
prevention and treatment. Tea, in fact, is a drug with good taste
and enjoyable. However, since the essential ingredients of CANAID
and YU-CCAN are pure herbs, CANAID and YU-CCAN should be classified
as drugs.
For the in-depth mechanism of function of CANAID and YU-CCAN,
more observations and research are underway. |
| |
|
---------------------------------------------------------------------------------------------
|
| |
Clinical
Report on the Therapeutic Effect
of CANAID and YU-CCAN from 39 Cases
|
|
|
| |
| In order to evaluate the clinical effect of Canaid and Yuccan
in China, we selected some cases from Guangdong province. The
results are summarized as follows: |
| |
| I.
Selection of Clinical Cases |
| |
| I. Tumor, Cancer |
| |
| The selection was based on the guidelines on clinical research
specified in the Law of Medicine - Anticancer Drugs. The standards
of diagnosis met the requirements of "Practical Internal
Medicine" (People's Health Publishing House, 8th Ed.,1986).
|
| |
| (1) Cancer patients confirmed by pathological histology
(or affirmed by cytologic diagnosis), or having definite marks
of tumor. The historical and cytologic specimen of the patients
was stored for recheck. |
| |
| (2) The subjects should be those for whom no routine
treatments were available or routine treatments had failed and
were willing to receive current treatments. |
| |
| (3) The performance status of the subject was between
0 and 3, and the subject was expected to live more than two months.
|
| |
| (4) Prior to the clinical test, the doctor in charge
would explain the conditions of the patient to the patient or
his/her family members (normally the family members), the nature
of the test, the potential benefits and risks, and obtain a written
agreement of the patient or his/her family members. |
| |
| The variety of the tumors tested was as diversified as possible.
In this test group, the distribution of the cases was as follows:
nasopharyngeal carcinoma: 5; pulmonary carcinoma: 4; hepatic carcinoma:
3; carcinoma of colon: 1; metracarcinoma 1; mammary cancer: 1;
adrenal tumor hepar metastasis:1; carcinoma ventriculi: 3; hepatic
cyst: 3; gall polypus:1; with the total being 23 cases. |
| |
| Among the cases selected, there were 13 male patients and 10
female patients, aged between 28 and 66, with an average of 48.6.
|
| |
| 2. Idiopathic and Secondary Immunologic Deficiency Diseases Caused by Imbalance of Immunologic System |
| |
| The standards of diagnosis met the requirements of "Practical
Internal Medicine" (People's Health Publishing House, 8th
Ed.,1986). The selection of this group of cases was mainly concentrated
on the patients with obvious clinical manifestation of secondary
immunologic deficiency diseases. The distribution of the cases
was as follows: chronic persisting hepatitis B: 4; pulmonary tuberculosis:
2; rhinallergosis: 2; coronary heart disease: 6; diabetes: 2;
with a total of 16 cases. |
| |
| Among the cases selected, there were 5 male and 11 female, aged
between 22 and 56, with an average of 40 |
| |
| II. Observation
Indices and Estimation Standards |
| |
| I. Tumor |
| |
| The tests were conducted according to the guidelines on clinical
research specified in the Law of Medicine-Anti-cancer Drugs |
| |
| (1) Anticancer
Effect |
|
Objective Estimation Standards of Therapeutical
Effect on Solid Tumor:
|
| |
| Complete Remission (CR): All observable pathologic changes
disappeared and the effect lasted for at least 4 weeks. |
| |
| Partial Remission (PR): The product of the largest perpendicular
diameters of the tumor focus decreased by more than 50%, and remained
so for at least 4 weeks. |
| |
| Moderate Remission (MR): The product of the two diameters
of the tumor focus decreased by more than 25%, but less than 50%,
and no new tumor focus appeared. |
| |
| Stabilized Development (SD): The product of the two diameters
of the tumor focus decreased or increased less than 25%, and no
new tumor focus appeared. |
| |
| Pathologic Development (PD): The product of the two diameters
of the tumor focus increased by more than 25%, or a new tumor
focus appeared. |
| |
| k Remission Rate: CR+PR (excluding MR and SD). |
| |
| Note: For the estimation standard of therapeutical effect
on leukemia and multiple myeloma, please refer to "Clinical
Research Guidelines on Drugs of Hematopathy". |
| |
| (2) Classification
Standards on Performance Status |
| |
| Class |
Performance
Status |
| |
|
| 0. |
Ability of movement was completely normal, and there was
no difference before and after the onset of the disease.
|
| |
|
| 1. |
The patient could walk freely and perform some light physical
activities, such as household chores, office work, but not
heavy labor work. |
| |
|
| 2. |
The patient could walk freely and take care of himself/herself,
but lost working capability. The patient might be active
no less than half of the time during daytime hours. |
| |
|
| 3. |
The patient could only take care of himself/herself partially,
and more than half of the time stayed in bed or was confined
to a wheelchair. |
| |
|
| 4. |
The patient was confined to a bed, and could not take
care of himself/herself. |
|
| |
| (3) Acute and Subacute
Toxicity Classification Standards of Anticancer Drugs |
| |
| |
Grade 0
|
Grade 1
|
Grade 2
|
Grade 3
|
Grade 4
|
Hb (g)
WBC (k)
Granulocyte (k)
Platelet (k)
Bleeding |
> 11.0
> 4.0
> 2.0
> 100
No
|
9.5~10.9
3.0~3.9
1.5~1.9
75~99
Light
|
< 9.5
2.0~2.9
1.0~1.4
50~74
Moderate
|
1.0~1.9
0.5~0.9
25~49
Heavy
|
< 1.0
< 0.5
< 25
Life
Threatening
|
Tract Nausea & Gastrointestinal Vomiting
Diarrhea |
No
No
|
Nausea
Short Time
(2 days)
|
Intermittent
Nausea
(controllable)
Bearable
(> 2 days)
|
Vomiting
(need
treatment)
Need
Treatment
|
Vomiting
(Uncontrollable)
Hematic
Diarrhea
|
| Billifuscin |
<1.25N
|
(1.26~2.5)N
|
(2.8~5)N
|
(5~10)N
|
>10N
|
| Serum Aminotransferase |
< 1.25*N
|
(1.26~2.5)N
|
(2.6~5)N
|
(5~10)N
|
>10N
|
|
Note: N = Normal Value;
*Translators note: The original value of 12.5 is obviously
a mistake.
|
| Stomatitis |
No
|
Painful
Erythema
|
Ulcer
Could Eat
|
Ulcer, Intake
Liquid Only
|
Ulcer
No Intake
|
Urinary System
BUN (mg%) |
< 20
|
21 - 40
|
41 - 60
|
> 60
|
Symptomatic
Uremia
|
Creatine
Proteinuria |
> 1.2
No
|
1.3 - 2.0
+
|
2.1 - 4.0
+ +
|
> 4.0
+ + +
|
Same as above
+ + + +
|
| Hematuria |
No
|
Microscope
Observable
|
Naked Eye
Observable
|
Naked Eye
Observable
Blood Clot
|
Complicating
Urinary Tract
Obstruction
|
Toxic Symptom of the
Lung ( Record
observations from X-ray
Film of the Chest) |
No
|
Light
|
Breathing
Difficulty
After
Activity
|
Breathing
Difficulty
At Rest
|
Always
Confined
to Bed
|
| Heart Rate & Rhythm |
Normal
|
Sinus
Tachycardia
100/min.
at Rest
|
Single-focus
Premature
Beat
|
Multi-focus
Premature
Beat
|
More Acute
Arryhythmia
|
| Skin |
Normal
|
Erythema,
Pigmentation
|
Blisters,
Itching, Dry
Desquamation
of Skin
|
Moist
Desquamation
of Skin, Ulcer
|
Exfollative
Dermatitis
Necrosis
|
| Hair |
Normal
|
Light
Alopecia
|
Moderate
Alopecia
|
Complete
Alopecia
Regeneratable
|
Compete
Alopecia
Non-
Regeneratable
|
|
Nervous System Mentality
Peripheral Nerve
|
|
Short-time
Lethargy
Sensation
Abnormal
or Tendon
Hyporeflexia
|
< 50%-time
Lethargy
Acute
Sensation
Abnormal
or Light
Asthenia
|
>50%-time
Lethargy
Unbearable
Sensation
Abnormal
or Obvious
Dyskinesia
|
|
| Constipation |
No
|
Light
|
Moderate
|
Abdominal
Distension
|
Enteroparalysis
|
|
| |
| (4) Calculation
methods of remission stage and survival period |
| |
| Remission stage: |
CR (Complete Remission): The time period between
the onset of CR and the onset of recurrence.
PR (Partial Remission) The time period between the
onset of PR and the time when the product of the two diameters
increased to 1/3 of that before the treatments. |
|
| Survival Period: |
| The time period between the commence of chemotherapy and
the time when the patient died or the last treatment (specifying
if the patient was still alive). |
|
| Anosis Survival
Period: |
| The time period between the commence of chemotherapy and
the onset of recurrence or the time when the CR patient
died (not applicable for non-CR patient). |
|
| |
| 2. Low
or Deficient Immunologic Function |
| |
(1). Immunologic
Indices:
(i) T Cell Subgroup OKT3,OKT4,OKT*,
OKT4/PKT8
*The subscript for this was not legible on the
original document. |
| Effective: |
Before treatment, the Tcell subgroup index was lower or
higher than normal, while after treatment, the T cell index
returned to normal or near normal. |
| Ineffective: |
After treatment, the abnormal index value had no statistically
significant change compared to the value before treatment
or that of a control group. |
| Exacerbating: |
After treatment, the abnormal Index value became more
obvious compared to that of the control group. |
|
| |
| (n) Lymphocyte Transformation Test |
| Effective: |
Abnormal lymphocyte transformation rate became normal
or close to normal after treatment. |
| Ineffective: |
The abnormal lymphocyte transformation rate had no significant
change after treatment. |
| Exacerbating: |
The treatment made the lymphocyte transformation rate
more abnormal (lower) compared to that of the control |
|
| |
| (ni) B Cell Function and Determination of Immunoglobulin
Determine the values of IgG, IgM, IgE and IgA. |
| (2) |
General Indices
(i) General check: Complete physical examination, pulse
rate, breath, blood pressure.
(ii) Blood routine examination, routine uronoscopy, feces
routine examination.
(iii) Liver function, blood bilirubin, serum glutamic pyruvlc
transaminase, alkaline phosphatase, albumin-globulin ratio.
(iv) Renal function, urea nitrogen. |
| (3) |
Electrocardiogram |
| (4) |
Overall Evaluation |
|
| Healing: |
Symptoms disappeared; physical signs basically returned
to normal; objective indices returned to normal, especially
the immunologic indices. Effects were stable after withdrawal
of drugs for along time (more than one year) |
| Notably
Effective: |
Symptoms basically disappeared; physical signs and objective
indices, especially immunologic indices, basically returned
to normal. |
| Effective: |
Symptoms, physical signs and objective indices improved
obviously compared to those of the control group. |
| Ineffective: |
Symptoms, physical signs and laboratory examination results
fluctuated, immunologic indices had little change compared
to those of the control group. |
| Exacerbating: |
Symptoms, physical signs and laboratory examination results
exacerbated, and the sickness became notably more severe
compared to those of the control group, and the immunologic
indices became more abnormal. |
|
| |
| III. Observation Methods |
| |
| 1. |
Among the tumor patients, three were on their advanced
stage and were of multiple and metastatic type, hence were
treated with the addition of "CANAID" and "YU-CCAN"
to their existing treatment plan. For the remaining twenty
patients, all the related drugs were stopped to give way
to the two testing drugs. |
| 2. |
For the patients of immunologic deficiency, all the other
»related drugs were stopped in order to use these
two drugs. |
| 3. |
Before observation, the patient was given a complete
examination with the results recorded, and then the tumor
patient underwent a clinical observation daily. |
| A complete reexamination was conducted monthly;
patients of immunologic deficiency were reexamined weekly;
the course of treatment for both tumor and immunologic deficiency
patients was one month. Estimation was performed by comparing
the examination records before and after the treatment.
|
| 4.
Method of administration and dosage: Oral administration
was used for all patients. |
| |
(1) Tumor patients: |
CANAID: 90 ml T.I.D. x 90 Days YU-CCAN:
20 ml B.I.D. x 90 Day |
| |
(2) Immunologic deficiency
patients: |
CANAID: 60 ml B.I.D. x 30 Days or 90
ml B.I.D. x 30 Days YU-CCAN: 30 ml Q.D. x 30 Days |
| Note: CANAID was administered
with empty stomach and with same amount of warm distilled
water. |
|
| 5.
Criteria for exclusion |
| |
(1) Pregnant or breast feeding women,
infants. |
| |
(2) When the patient or his/her
family members did not agree to receive the current
medicine treatment. |
|
|
| |
| IV. Results |
| |
| 1.
Therapeutic Effect on Tumor |
| |
| (1) |
Anticancer effect: complete remission (CR)1
case, partial remission (PR) 6 cases, and death 3
cases. Total remission rate: 7 Cases (7/23=30.43%);
Improvement (MR) + Stabilization (SD) 13 cases=56.52%;
death 3 cases=13.04%. |
| (2) |
Performance status (Number of cases, before
and after the treatment)
| Grade |
0
|
1
|
2
|
3
|
4
|
| Before Treatment |
0
|
3
|
5
|
3
|
12
|
| After Treatment |
1
|
8
|
6
|
3
|
2
|
3 Deaths
|
| (3) |
Other effect Among the 23 cases of tumor patients:
21 had various degrees of improvement on spirit,
appetite, and digesting ability. Their defecation
function (hard to defecate, no shape) also improved.
Their faces looked much more healthy. Six cases of
low WBC had their WBC returned normal. Three cases
with high SGPT all had decreased SGPT, and two of
the three returned normal. |
| (4) |
Toxic side reaction:
| 1 |
Among the 23 cases, 9 had
dizziness the next morning following the administration
of the drugs, lasting from 2 to 6 days; of
the 9 cases, 2 remitted through intravenous
injection of 50% GS, other cases were bearable,
and the symptom disappeared naturally in 3
to 7 days. The effectiveness of the drugs
was not affected.
|
| 2 |
Among the 23 cases, 5 had
more frequent defecation with pulpy excrement
2 to 7 days following the administration of
the drugs. No measures were taken and the
symptom remitted spontaneously. For these
patients, there were no abdominalgia and diarrhea,
and they felt comfortable after defecation.
Three patients had constipation.
|
| 3 |
For the 20 surviving patients,
throughout the observation period, no abnormal
changes were shown on their blood routine
examination, routine uronoscopy, SGPT, or
BUN.
|
| 4 |
Three cases had periodic hematochezia
(carcinoma ventriculi and hepatic carcinoma
patients), and one case had intermittent blood
tinged sputum (pulmonary carcinoma patient).
The above symptoms were treated and eased
without stopping the main treatment drugs.
The effectiveness of the testing drugs was
not affected
|
| 5 |
For the 19 cases with ECG records to compare,
no abnormal changes were observed. |
|
|
| |
|
| 2.
Therapeutic Effect on Immunologic Deficiency |
| |
| (1) |
Overall Evaluation |
| |
| Notably Effective: |
5 cases: rhinallergosis - 2; chronic
persisting hepatitis B - 2; coronary heart disease
- 1 |
| Effective: |
8 cases: chronic persisting hepatitis
B - 2; pulmonary TB -2; coronary heart disease
-3; diabetes -1. |
| Ineffective: |
3 cases: coronary heart disease -2;
diabetes -1 |
|
| (2) |
Immunologic Indices Evaluation |
| |
| Of the 16 cases in this group, 7 had Immunoglobulin
determination results before and after the treatment
to compare with. The results are as follows
(The in-column figures are the results). |
|
| |
| Index |
Patient
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
| lgA |
Before
After
|
0.9
1.35
|
0.94
1.55
|
1.0
1.8
|
1.0
1.68
|
0.4
1.0
|
0.5
1.1
|
1.8
1.8
|
| lgG |
Before
After
|
6.3
9.8
|
6.0
10.8
|
8.0
10.35
|
8.0
10.3
|
5.0
9.5
|
5.5
10.2
|
15.58
11.6
|
| lgM |
Before
After
|
1.0
1.15
|
1.25
1.35
|
1.1
1.25
|
0.9
1.25
|
0.6
1.1
|
0.5
1.1
|
0.78
1.8
|
| lgE |
Before
After
|
0.06
0.4
|
1.33
0.78
|
1.15
0.9
|
1.2
0.8
|
1.3
0.82
|
1.58
0.82
|
0.06
0.3
|
| Normal Values: |
lgA: 1.2~2.3 |
lgG; 8.0~14.5 |
lgM; 0.8~1.95 |
lgE; 0.1~0.9 |
|
|
| |
Patient 1:
Patient 2:
Patient 3:
Patient 4:
Patient 5:
Patient 6:
Patient 7: |
Li - chronic persisting hepatitis B
Hu - coronary heart disease
Wu - rhinallergosis
Chen - pulmonary TB
Ou - chronic persisting hepatitis B
Liang - rhinallergosis
Lu - chronic persisting hepatitis B |
|
| (3) |
Various specific determination results |
| |
| 1 |
Chronic persisting hepatitis B - 4 cases: |
| |
| Case |
|
Li
( Female)
24
|
Zhong
(Female)
43
|
Lu
(Male)
38
|
Chen
(Female)
19
|
| HBS Ag |
Before
After |
+
+/-
|
+
+
|
+
-
|
+
+/-
|
| HBe Ab |
Before
After |
-
-
|
-
-
|
-
-
|
-
-
|
| HBe Ag |
Before
After |
+
+
|
+
-
|
+
-
|
+
-
|
| HBe AB |
Before
After |
-
-
|
-
+/-
|
+
-
|
+
+
|
| HBC AB |
Before
After |
+
+
|
+
+
|
+
+
|
+
+
|
| HBS Titer |
Before
After |
>1:256
>1:64
|
.
|
>1:256
>1:8
|
>1:256
>1:16
|
| SGPT |
Before
After |
25
24
|
35
22
|
27
23
|
93
22
|
| Dizziness |
Before
After |
-
-
|
+
-
|
-
-
|
+
-
|
Sodium
Difference |
Before
After |
+
-
|
+ +
-
|
+
-
|
+
-
|
| Asthenia |
Before
After |
+
-
|
+ +
-
|
+ +
-
|
+ +
-
|
| Acne |
Before
After |
+ +
-
|
+ +
-
|
+
-
|
+ +
-
|
| Pigment Spots |
Before
After |
+ +
-
|
+ + +
-
|
-
-
|
+ +
-
|
Abdominal
Distension |
Before
After |
+
-
|
+ +
-
|
+
-
|
+
-
|
| Hepatalgia |
Before
After |
-
-
|
+
-
|
+
-
|
+/-
-
|
| Estimation |
Effective
|
Notably
Effective
|
Effective
|
Notably
Effective
|
|
| |
|
| 2 |
The symptoms of the two patients with pulmonary
TB had notable improvement: the afternoon hectic
fever basically disappeared, physical strength
was recovered, cough largely disappeared, appetite
was improved, body weight gained, X-ray TB shadow
had no expansion. |
| 3 |
The two cases of rhinallergosis had no occurrence
during the administration of the drugs and 20
to 30 days after the withdrawal of the drugs. |
| 4 |
Of the six cases of coronary heart disease,
the ST-T ECG of the four patients with ischemic
symptom had improvement, with one having notable
improvement, and none of the four had angina
pectoris occurrence during the administration
of the drugs. The rest two, cases had no change. |
| 5 |
Of the two cases of diabetes, both had improvement
on their spirit and physical strength, and the
fasting blood-glucose concentration of one of
the two patients dropped from Sg/L to 6.8g/L;
the other one had no improvement. |
|
| (4) |
Toxic side reaction: |
| |
Of the sixteen cases in this group, two had light
morning dizziness 2 to 5 days after the commence of
the drug administration, and no treatment was involved
before spontaneous remission. Blood and urine routine
examinations showed no abnormal results, and the occult
blood in stool was negative. Other cases had no notable
toxic side reaction. |
|
|
| |
| V. A Typical
Case |
| |
| Patient name: Ma - gender: male; Age: 36; occupation:
electrician. |
| |
| In the beginning of August,1993, feeling tinnitus and hypoacusis
the patient visited the People's Hospital of Guangdong Province.
Physical examination revealed that in his nasopharynx, there were
cauliflower-like foci on the top back, right side and above. The
illness was diagnosed as nasopharyngeal carcinoma through biopsy.
At that time, the patient's body weight was 68.5 kg, had no symptoms
of nosebleed, headache. No swelling of lymphoid cervicales and
abnormal cranial nerves were observed. Fluoroscopy of chest did
not show abnormal heart and lung. Ultrasonic examination did not
reveal anything abnormal with the liver, spleen, and gallbladder.
Laboratory test showed WBC 4.9x10', RBC 4.5x10", and Hb 136
g/L. Following confirmed diagnosis, the patient was treated with
simple radiotherapy. The treatment was divided into a few periods
(with 28 days rest), with a total of 33 visits in 75 days (from
August 2 to October 14, 1993). During the time of radiotherapy,
the patient had a decreased appetite, had dizziness, and the body
weight reduced to 62 kg. Upon finishing the radiotherapy treatment
on October 14, 1993, examination of nasopharynx found local swelling
on the right protuberance, and residual lesser tubercle. Physical
examination did not reveal abnormalities in the heart, lung, liver,
spleen; and gallbladder. Physical examination on January 4,1994
still found the lesser buninoid process on the right protuberance
lesser tubercle. The patient had severe dizziness and asthenia.
Since the WBC counting was only 3.0x10', no further radiotherapy
might be sustained. In April, 1994, the patient started taking
CANAID and YUCCAN with the dosage being: Canaid, 60 ml B.I.D.,
and Yuccan 30 ml Q.D. In the first week, the patient had diarrhea,
but no abdominalgia and rectal tenesmus. The frequency of defecation
was once to twice a day, with yellowish watery and pulpy stool.
The patient complained with bearable asthenia universalis with
no fever and headache. No other treatment was conducted. Another
two weeks of administering the two drugs resulted in normalized
defecation and recovered physical strength. The frequent dizziness
and giddiness complained before the treatment disappeared and
the appetite increased. The dosage for Canaid was then increased
to 60 ml T.I.D. And that of Yuccan remained the same. The physical
examination on May 10,1994 revealed that the lesser tubercle on
the right protuberance of nasopharynx had become flattened. The
conditions of heart, lung, liver and spleen were all normal. Afterwards,
the patient continued taking Canaid and Yuccan, and came to the
hospital for regular physical examination each month. The physical
examination on November 8, 1994 found that the tubercle on the
right protuberance of the nasopharynx had disappeared, and there
were scattered condensed secreta, no swelling on the cervical
lymph node. Cranial nerves, heart, lung, liver and spleen were
all normal. On March 20, 1995, physical examination showed that
the original focus had disappeared, no obvious secreta were seen
on the surface. The patient's self-feeling was good and had been
working regularly. Currently, the patient is still taking Canaid
at 60 ml Q.D. And Yuccan at 30 ml Q.D., And has been undergoing
a tracing observation. |
| |
| Vl. Discussion |
| |
| Of the thirty-nine cases in this group of study, twenty-three
were tumor patients, sixteen were secondary immunologic deficiency
patients. Among the twenty-three tumor patients, three died of
advanced metastatic carcinoma, since they had been already at
a critical stage when starting the current treatment. There was
one case of complete remission, six cases of partial remission,
thirteen cases of moderate remission, and stabilized development.
The total remission rate was 30.43%. The rate of moderate remission
and stabilized development was 56.52%. The death rate was 13.04%.
Of the sixteen secondary immunologic deficiency cases, five were
notably effective, eight were effective, and three were ineffective.
During the whole period of observation, the combined use of Canaid
and Yuccan on tumor treatment had about the same effectiveness
as that reported from Hong Kong and Canada. In addition, there
were no toxic side reactions as seen with other Anticancer drugs,
such as arrest of bone marrow, digestive tract reaction, reaction
of tunica mucosa oris, baldness. On the contrary, with the current
treatment, all the patients in the study group had improvements
in spirit, appetite, digestive function, physical strength, and
immunologic function of the body. The drugs were also shown effective
on hepatitis 8, rhinallergosis, pulmonary TB and coronary heart
disease. Therefore, the drugs are notably better than other antitumor
drugs. In 1959 Dr. Charles Mclluce of Canada showed that Canaid
could reduce the size of tumor on the body of mice, and change
the tissue of cells. The tests on patients showed that Canaid
could decrease the size of tumor, alleviate pain, increase body
weight, and improve the overall health of the patient. |
| |
| As described by The Encyclopedia of Natural
Health, 1994 edition, CANAID Herbal Tea (CANAID), which has
been used in Canada and United States for over seventy years "Is
believed to be a major breakthrough in the field of cancer treatment
and prevention, and this has been awaiting by the world for a
long time". |
| |
|
|
| |
| |
| |
|
